Bronchiectasis Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The bronchiectasis drugs market is expected to increase from USD 1.68 billion in 2025 to USD 2.66 billion in 2026, to reach USD 5.28 billion by 2031, growing at a CAGR 14.69% over 2026-2031. This report is segmented by Drug Class (Antibiotics, Mucolytics and Expectorants, and More), Route of Administration (Inhalational and More), Patient Type (Adults and More), Distribution Channel (Hospital Pharmacies and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Bronchiectasis Drugs Market Trends and Insights

Rising Diagnosis of Bronchiectasis Through High-Resolution CT and Microbiology

Respiratory specialists increasingly identified bronchiectasis when assessing patients with persistent asthma or COPD symptoms using high-resolution CT. The WHO identified chronic respiratory disease as a key setting for earlier diagnosis and coordinated respiratory care. As a result, specialist consultations for obstructive lung disease became an important pathway to bronchiectasis diagnosis and subsequent treatment. A 2026 European Respiratory Society review reported rising prevalence across multiple cohorts as diagnostic capacity improved. The European Medicines Agency granted PRIME support to brensocatib, reflecting the unmet need in NCFB and a clearer regulatory pathway for disease-specific therapies. The bronchiectasis drugs market could expand as more diagnosed patients moved from general respiratory care into specialist treatment pathways.

Recurrent Exacerbations and Long-Term Antibiotic Utilization

A 2025 randomized trial found that dual and triple inhaled bronchodilator regimens reduced exacerbations among bronchiectasis patients with airflow obstruction. The findings strengthened the clinical rationale for long-acting combination therapies in patients with coexisting obstructive respiratory disease. This supported demand for products such as GSK’s Trelegy Ellipta and AstraZeneca’s Breztri Aerosphere. The 2025 European Respiratory Society guideline advised against routine inhaled corticosteroid use in patients without asthma or COPD while maintaining its role for eligible patients. The guidance focused treatment on appropriate patient populations and supported recurring prescription demand in the bronchiectasis drugs market.

Device Burden and Adherence Challenges in Chronic Nebulized Therapy

Correct inhaler technique remains essential for patients to achieve expected treatment benefits. Uneven access to telehealth support and specialist guidance creates gaps in respiratory care. Incorrect inhaler use may make patients appear unresponsive despite appropriate therapy, prompting unnecessary medication changes. The European Respiratory Society guideline requires careful patient selection for inhaled corticosteroids, which remains challenging without regular respiratory monitoring. These gaps limit treatment outcomes and slow the adoption of higher-value inhaled regimens in the bronchiectasis drugs market.

Other drivers and restraints analyzed in the detailed report include:

• Precision Stratification by Neutrophilic and Eosinophilic Phenotypes
• Home-Based Nebulization and Digital Adherence Monitoring
• Antimicrobial Resistance and Diminishing Antibiotic Durability

Segment Analysis

Antibiotics accounted for 38.59% of the bronchiectasis drugs market in 2025. Recent clinical evidence continues to strengthen the antibiotics subsegment in the bronchiectasis market. A July 2024 meta-analysis published in CHEST confirmed that inhaled antibiotics significantly reduce exacerbation frequency and sputum bacterial load in adults with bronchiectasis, supporting greater adoption of long-term suppressive antibiotic therapy. Additionally, the January 2024 ERASE trial demonstrated the effectiveness of inhaled tobramycin, with or without oral ciprofloxacin, for eradicating Pseudomonas aeruginosa, validating combination antibiotic approaches for chronic infection management. Together, these findings are expected to boost physician confidence, support guideline-based use, and drive growth of the antibiotics subsegment in bronchiectasis treatment.

DPP-1 and Cathepsin C inhibitors are projected to grow at a CAGR of 24.25% through 2031, making them the fastest-growing drug class. Recent clinical advancements have strengthened the emerging DPP-1 and cathepsin C inhibitor subsegments in the bronchiectasis drugs market. The Phase III ASPEN trial demonstrated that the DPP-1 inhibitor brensocatib reduced exacerbations in bronchiectasis patients, providing a strong foundation for disease-modifying therapy. Additionally, the Phase II AIRLEAF trial reported positive dose-finding results for the cathepsin C inhibitor BI 1291583, supporting pipeline expansion and increasing the future therapeutic options available for bronchiectasis management.

Oral route of administration accounted for 50.09% of the bronchiectasis drugs market in 2025, and it is also expected to be the fastest-growing segment with a projected CAGR of 17.97% thorugh 2031. Brensocatib introduced an oral, once-daily treatment option designed specifically for non-cystic fibrosis bronchiectasis (NCFB). The broader DPP-1 inhibitor class may create additional oral treatment options following the first commercial entry. A 2025 meta-analysis found that DPP-1 inhibitors reduced exacerbation frequency by 27%, with a risk ratio of 0.73 and moderate-certainty evidence. Oral therapies may support homecare and specialty clinic models by reducing device-handling requirements and enabling treatment outside hospitals.

Oral azithromycin remained an important treatment option for preventing pulmonary exacerbations in bronchiectasis. A 2025 systematic review and meta-analysis involving 562 patients across six randomized controlled trials confirmed its efficacy in reducing exacerbation frequency, reinforcing the clinical value of oral antibiotic therapy and supporting continued growth of the oral-route segment in the market.

Complete Report Scope:

• By Drug Class
  • Antibiotics
  • Mucolytics and Expectorants
  • Bronchodilators
  • Anti-Inflammatory Agents
  • DPP-1 and Cathepsin-C Inhibitors
  • Biologic Therapies
  • Other Drug Classes
• By Route of Administration
  • Inhalation
  • Oral
  • Parenteral
• By Patient Type
  • Adults
  • Older Adults
  • Pediatric Patients
• By Distribution Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail and Community Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held a 44.75% share of the bronchiectasis drugs market in 2025. The United States has the largest commercially addressable diagnosed NCFB population and the most developed specialty reimbursement infrastructure. Insmed estimated that the United States had 500,000 diagnosed NCFB patients, with half potentially meeting the clinical eligibility criteria for brensocatib. Brinsupri had an annual list price of USD 88,000 per patient in the United States, supporting higher revenue per treated patient. Canada and Mexico added demand for bronchodilators and corticosteroids, although access to disease-specific therapies developed more slowly.

Europe was the second-largest regional market for bronchiectasis drugs. The European Commission authorized Brinsupri in November 2025 for patients aged 12 years and older with at least two exacerbations in the preceding 12 months. Pricing and reimbursement negotiations across member states can delay broad commercial access. The EMA estimated that 400,000 to 3 million people in the European Union had NCFB, highlighting uneven diagnosis and disease recording. Germany, the United Kingdom, and France remained key early-access markets, while the United Kingdom authorized Brinsupri in February 2026 for eligible patients aged 12 years and older.

Asia-Pacific is forecast to grow at a CAGR of 17.25% through 2031, the highest regional rate in the bronchiectasis drugs market. China reported a prevalence of 1,200 per 100,000 people aged 40 years and older, and the BE-China registry improved visibility into the country’s patient population. Insmed expected a Japanese regulatory decision for brensocatib in the second half of 2026. South Korea reported a prevalence of 886 per 100,000 adults, indicating significant treatment demand, while tuberculosis-related lung damage remained a major cause of bronchiectasis in India. The Middle East and Africa and South America held a combined share below 15% in 2025, where tender procurement and access constraints favored generic respiratory therapies.

List of Companies Covered in this Report:

• ACI Pharmaceuticals Ltd
• AdvaCare
• ALTURiX Ltd
• Armata Pharmaceuticals, Inc.
• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Cameron Pharmaceuticals, LLC
• Chemax Pharma
• Chiesi Farmaceutici
• Cipla
• Fresenius
• GlaxoSmithKline
• Insmed
• Merck
• Pfizer
• ReVagenix, Inc.
• Sanofi
• STELLAPHARM J.V. CO., LTD
• Teva Pharmaceutical Industries
• Unilab, Inc.
• Viatris
• Zambon S.p.A.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support